RT Journal Article
T1 Correction to: A phase I-II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia.
A1 Martínez-Cuadrón, David
A1 Boluda, Blanca
A1 Martínez, Pilar
A1 Bergua, Juan
A1 Rodríguez-Veiga, Rebeca
A1 Esteve, Jordi
A1 Vives, Susana
A1 Serrano, Josefina
A1 Vidriales, Belen
A1 Salamero, Olga
A1 Cordón, Lourdes
A1 Sempere, Amparo
A1 Jiménez-Ubieto, Ana
A1 Prieto-Delgado, Julio
A1 Díaz-Beyá, Marina
A1 Garrido, Ana
A1 Benavente, Celina
A1 Pérez-Simón, José Antonio
A1 Moscardó, Federico
A1 Sanz, Miguel A
A1 Montesinos, Pau
A1 CETLAM and PETHEMA groups, 
AB The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández in the original article.The original version of this article was revised: The name of Pau Montesinos was inadvertently presented as Pau Montesinos Fernández.
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12172
UL http://hdl.handle.net/10668/12172
LA en
DS RISalud
RD Apr 18, 2025